MassBio CEO & President Kendalle Burlin O’Connell posted this update to LinkedIn.
The last two weeks brought encouraging momentum for the industry, from record-breaking capital raises around JPM to Massachusetts leading the nation on patient access reforms. While policy challenges from Washington persist (we’ll have more to say about the White House announcement just hours ago), I’ll be heading to DC next week for conversations on the industry’s challenges and opportunities. We remain committed to advocating for policies that support innovation and ensure patients can access the breakthrough treatments our industry develops.
- JPM 2026: The 2026 J.P. Morgan Healthcare Conference, held in San Francisco, CA, opened with renewed momentum in biotech capital markets, with companies raising $4.9 billion in the week leading up to the event, including $2.6 billion in public offerings, making this the strongest start to the year on record, and $2.29 billion in private rounds. MassBio was in San Francisco for the week, hosting events and connecting with members.
- Massachusetts life sciences companies made significant announcements, demonstrating the state’s continued leadership in healthcare innovation. Charles River Laboratories unveiled two strategic acquisitions totaling over $500 million to strengthen its non-human primate supply chain and biopharmaceutical testing capabilities. Additionally, Biogen showcased a revitalized pipeline focused on neuroscience and rare disease, while Boston Scientific highlighted explosive growth, projecting 15% annual growth for at least another three years.
- Beyond corporate presentations, the conference also spotlighted broader regulatory concerns as former FDA official Richard Pazdur warned that the firewall between political appointees and drug reviewers has been breached, raising questions about transparency in the agency’s new voucher program that could impact the approval pathway for drugs being developed across the country.
- Prior Authorization Reforms: Governor Healey announced nation-leading reforms to streamline prior authorization processes, making it faster and easier for Massachusetts patients to access the medications they need. The new regulations will reduce administrative barriers that delay care, ensuring patients can get timely access to the innovative treatments developed by the Commonwealth’s life sciences industry. I’m honored to have been appointed to the Governor’s Working Group on healthcare cost reduction, where we’ll work to find creative solutions that balance affordability with patient access to breakthrough therapies.
- Pharma Tariffs and MFN Update: According to a new “Letter of Agreement”, the Department of Commerce appears to have concluded its Section 232 investigation into pharmaceutical imports. The document outlines the latest framework for MFN drug pricing deals and recent momentum in onshoring. According to the law, President Trump has 90 days to decide whether to act based on the report’s findings, so we can expect to see such actions within the next few months.
- FDA Issues Guidance on Modernizing Statistical Methods for Clinical Trials: The FDA published draft guidance to facilitate the use of Bayesian methodologies in clinical trials for drugs and biologics. The agency emphasized that Bayesian approaches, which combine current trial data with relevant prior information, can help reduce development costs and timelines while maintaining rigorous safety and efficacy standards. According to FDA Commissioner Marty Makary, providing clarity on these modern statistical methods will help sponsors bring more treatments to patients faster and more affordably.
- 2026 Health Package Outlook: Congress continues to debate a healthcare package, with some members intent on reviving bipartisan priorities. The current focus of the package includes PBM reform and increased control on Medicare outpatient spending, along with renewing existing programs, such as telehealth options and community health centers. Senate Finance Ranking Member Ron Wyden (D-OR) recently referenced the 26-0 Committee vote in favor of PBM overhaul in 2023, and feels upbeat about getting it over the finish line, Meanwhile, Senate Finance Chairman Mike Crapo (R-ID) noted “broad support here and at the White House” for the PBM bill, which would “delink” the price of a drug from PBM compensation in Medicare Part D. Extension of ACA subsidies are likely to be excluded from any such legislation.
- NSCEB Releases New Biotech Regulatory Recommendations: The National Security Commission on Emerging Biotechnology (NSCEB) released new analysis and 83 policy options to modernize and accelerate U.S. regulatory review of biotechnology products across medical, plant, microorganism, and animal sectors. Across the 22 medical recommendations, there is an emphasis on predictability and transparency to ensure faster clinical trials and promote more efficient manufacturing. The proposals aim to streamline fragmented processes, reduce regulatory burden, and help U.S. innovators compete globally, particularly against China, while maintaining safety standards. NSCEB leadership emphasized that faster, more predictable oversight will strengthen national security, attract investment, and support economic growth.